Invention Grant
- Patent Title: Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
-
Application No.: US16317606Application Date: 2017-07-14
-
Publication No.: US11613586B2Publication Date: 2023-03-28
- Inventor: Glennda Smithson , Jose Estevam , Nicholas Jones
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Agency: Morgan, Lewis & Bockius LLP
- International Application: PCT/US2017/042128 WO 20170714
- International Announcement: WO2018/013917 WO 20180118
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P19/02 ; G01N33/569 ; A61K39/00
Abstract:
The present disclosure relates to anti-CD38 antibodies and their use as therapeutics and diagnostics. The present disclosure further relates to methods of treating autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis. The present disclosure further relates to diagnostic assay methods for identifying patients having autoimmune diseases for treatment.
Public/Granted literature
- US20190322756A1 METHODS AND MATERIALS FOR ASSESSING RESPONSE TO PLASMABLAST- AND PLASMA CELL-DEPLETING THERAPIES Public/Granted day:2019-10-24
Information query
